CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease
α-Synuclein, a key pathological component of Parkinson's disease, has been implicated in the activation of the innate and adaptive immune system. This immune activation includes microgliosis, increased inflammatory cytokines, and the infiltration of T cells into the CNS. More recently, peripher...
Uloženo v:
| Vydáno v: | Brain (London, England : 1878) Ročník 144; číslo 7; s. 2047 |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
17.08.2021
|
| ISSN: | 1460-2156, 1460-2156 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | α-Synuclein, a key pathological component of Parkinson's disease, has been implicated in the activation of the innate and adaptive immune system. This immune activation includes microgliosis, increased inflammatory cytokines, and the infiltration of T cells into the CNS. More recently, peripherally circulating CD4 and CD8 T cells derived from individuals with Parkinson's disease have been shown to produce Th1/Th2 cytokines in response to α-synuclein, suggesting there may be a chronic memory T cell response present in Parkinson's disease. To understand the potential effects of these α-syn associated T cell responses we used an α-synuclein overexpression mouse model, T cell-deficient mice, and a combination of immunohistochemistry and flow cytometry. In this study, we found that α-synuclein overexpression in the midbrain of mice leads to the upregulation of the major histocompatibility complex II (MHCII) protein on CNS myeloid cells as well as the infiltration of IFNγ producing CD4 and CD8 T cells into the CNS. Interestingly, genetic deletion of TCRβ or CD4, as well as the use of the immunosuppressive drug fingolimod, were able to reduce the CNS myeloid MHCII response to α-synuclein. Furthermore, we observed that CD4-deficient mice were protected from the dopaminergic cell loss observed due to α-syn overexpression. These results suggest that T cell responses associated with α-synuclein pathology may be damaging to key areas of the CNS in Parkinson's disease and that targeting these T cell responses could be an avenue for disease modifying treatments.α-Synuclein, a key pathological component of Parkinson's disease, has been implicated in the activation of the innate and adaptive immune system. This immune activation includes microgliosis, increased inflammatory cytokines, and the infiltration of T cells into the CNS. More recently, peripherally circulating CD4 and CD8 T cells derived from individuals with Parkinson's disease have been shown to produce Th1/Th2 cytokines in response to α-synuclein, suggesting there may be a chronic memory T cell response present in Parkinson's disease. To understand the potential effects of these α-syn associated T cell responses we used an α-synuclein overexpression mouse model, T cell-deficient mice, and a combination of immunohistochemistry and flow cytometry. In this study, we found that α-synuclein overexpression in the midbrain of mice leads to the upregulation of the major histocompatibility complex II (MHCII) protein on CNS myeloid cells as well as the infiltration of IFNγ producing CD4 and CD8 T cells into the CNS. Interestingly, genetic deletion of TCRβ or CD4, as well as the use of the immunosuppressive drug fingolimod, were able to reduce the CNS myeloid MHCII response to α-synuclein. Furthermore, we observed that CD4-deficient mice were protected from the dopaminergic cell loss observed due to α-syn overexpression. These results suggest that T cell responses associated with α-synuclein pathology may be damaging to key areas of the CNS in Parkinson's disease and that targeting these T cell responses could be an avenue for disease modifying treatments. |
|---|---|
| AbstractList | α-Synuclein, a key pathological component of Parkinson's disease, has been implicated in the activation of the innate and adaptive immune system. This immune activation includes microgliosis, increased inflammatory cytokines, and the infiltration of T cells into the CNS. More recently, peripherally circulating CD4 and CD8 T cells derived from individuals with Parkinson's disease have been shown to produce Th1/Th2 cytokines in response to α-synuclein, suggesting there may be a chronic memory T cell response present in Parkinson's disease. To understand the potential effects of these α-syn associated T cell responses we used an α-synuclein overexpression mouse model, T cell-deficient mice, and a combination of immunohistochemistry and flow cytometry. In this study, we found that α-synuclein overexpression in the midbrain of mice leads to the upregulation of the major histocompatibility complex II (MHCII) protein on CNS myeloid cells as well as the infiltration of IFNγ producing CD4 and CD8 T cells into the CNS. Interestingly, genetic deletion of TCRβ or CD4, as well as the use of the immunosuppressive drug fingolimod, were able to reduce the CNS myeloid MHCII response to α-synuclein. Furthermore, we observed that CD4-deficient mice were protected from the dopaminergic cell loss observed due to α-syn overexpression. These results suggest that T cell responses associated with α-synuclein pathology may be damaging to key areas of the CNS in Parkinson's disease and that targeting these T cell responses could be an avenue for disease modifying treatments.α-Synuclein, a key pathological component of Parkinson's disease, has been implicated in the activation of the innate and adaptive immune system. This immune activation includes microgliosis, increased inflammatory cytokines, and the infiltration of T cells into the CNS. More recently, peripherally circulating CD4 and CD8 T cells derived from individuals with Parkinson's disease have been shown to produce Th1/Th2 cytokines in response to α-synuclein, suggesting there may be a chronic memory T cell response present in Parkinson's disease. To understand the potential effects of these α-syn associated T cell responses we used an α-synuclein overexpression mouse model, T cell-deficient mice, and a combination of immunohistochemistry and flow cytometry. In this study, we found that α-synuclein overexpression in the midbrain of mice leads to the upregulation of the major histocompatibility complex II (MHCII) protein on CNS myeloid cells as well as the infiltration of IFNγ producing CD4 and CD8 T cells into the CNS. Interestingly, genetic deletion of TCRβ or CD4, as well as the use of the immunosuppressive drug fingolimod, were able to reduce the CNS myeloid MHCII response to α-synuclein. Furthermore, we observed that CD4-deficient mice were protected from the dopaminergic cell loss observed due to α-syn overexpression. These results suggest that T cell responses associated with α-synuclein pathology may be damaging to key areas of the CNS in Parkinson's disease and that targeting these T cell responses could be an avenue for disease modifying treatments. |
| Author | Williams, Gregory P Schonhoff, Aubrey M Gallups, Nicole J Jurkuvenaite, Asta Standaert, David G Harms, Ashley S |
| Author_xml | – sequence: 1 givenname: Gregory P surname: Williams fullname: Williams, Gregory P – sequence: 2 givenname: Aubrey M surname: Schonhoff fullname: Schonhoff, Aubrey M – sequence: 3 givenname: Asta surname: Jurkuvenaite fullname: Jurkuvenaite, Asta – sequence: 4 givenname: Nicole J surname: Gallups fullname: Gallups, Nicole J – sequence: 5 givenname: David G surname: Standaert fullname: Standaert, David G – sequence: 6 givenname: Ashley S surname: Harms fullname: Harms, Ashley S |
| BookMark | eNpNj71PwzAQxS1UJNrCyO4NltCz49jNiMKnVAmGMlfn-IwMiQ1xKv59AmVgeXd6d_rpvQWbxRSJsXMBVwLqcmUHDHGFX2gFlEdsLpSGQopKz_7tJ2yR8xuAUKXUc-aaG8W3vKWuy7wnF3Ak_gviIfoO-x7HkCLH6Hik_ZAcvVKk4eBOX8j7tM80qaOOJ8-fcXgPMad4kbkLmTDTKTv22GU6-5tL9nJ3u20eis3T_WNzvSnaUquxsBK9lWINXqBopa1JKyOw9kYhWDA1rK0RnkhM6VvtbampUsZqPR08Orlklwfux5A-95THXR_yTzWMNIXcyQqgNEpLLb8BzTVc1g |
| CitedBy_id | crossref_primary_10_1016_j_jneuroim_2025_578755 crossref_primary_10_1038_s41593_023_01323_6 crossref_primary_10_1016_j_nbd_2024_106609 crossref_primary_10_3390_ijms23158175 crossref_primary_10_3390_md23030133 crossref_primary_10_1016_j_cej_2025_168308 crossref_primary_10_1016_j_biopha_2023_114541 crossref_primary_10_3389_fcell_2024_1510897 crossref_primary_10_1007_s10787_024_01595_9 crossref_primary_10_3390_ijms26136416 crossref_primary_10_3389_fnagi_2022_855776 crossref_primary_10_1186_s12974_024_03210_8 crossref_primary_10_1523_JNEUROSCI_0680_22_2022 crossref_primary_10_31083_FBL27178 crossref_primary_10_1002_mco2_70328 crossref_primary_10_3389_fimmu_2024_1432342 crossref_primary_10_3390_ijms242015237 crossref_primary_10_1186_s12974_024_03087_7 crossref_primary_10_3389_fmolb_2023_1292555 crossref_primary_10_1038_s41598_025_95679_3 crossref_primary_10_1126_sciadv_adp3672 crossref_primary_10_1038_s41531_025_00870_y crossref_primary_10_1126_scitranslmed_abq6089 crossref_primary_10_3390_ijms25105377 crossref_primary_10_3389_fimmu_2024_1442322 crossref_primary_10_1186_s12951_024_02428_1 crossref_primary_10_1186_s12974_025_03459_7 crossref_primary_10_3390_ijms25137406 crossref_primary_10_1038_s41380_024_02618_1 crossref_primary_10_1016_j_ejim_2025_106505 crossref_primary_10_1016_j_isci_2024_110243 crossref_primary_10_1038_s41467_025_62478_3 crossref_primary_10_4103_NRR_NRR_D_24_01063 crossref_primary_10_1021_acsnano_5c01068 crossref_primary_10_1016_j_immuni_2025_04_005 crossref_primary_10_3390_v14071493 crossref_primary_10_1186_s12967_023_04254_9 crossref_primary_10_1016_j_bbi_2024_05_004 crossref_primary_10_1111_imr_13419 crossref_primary_10_1016_j_compbiomed_2023_106801 crossref_primary_10_1073_pnas_2204058119 crossref_primary_10_1007_s12035_024_03948_5 crossref_primary_10_4103_1673_5374_387967 crossref_primary_10_31083_j_jin2311203 crossref_primary_10_1002_jcla_24542 crossref_primary_10_1038_s41419_025_07333_5 crossref_primary_10_1186_s40035_024_00445_6 crossref_primary_10_3389_fncel_2025_1627305 crossref_primary_10_3390_ijms241512116 crossref_primary_10_1016_j_nbd_2023_106308 crossref_primary_10_1016_j_nbd_2022_105654 crossref_primary_10_1038_s41531_025_00882_8 crossref_primary_10_1080_17460441_2023_2160440 crossref_primary_10_1186_s12974_023_02956_x crossref_primary_10_1038_s41590_025_02200_z crossref_primary_10_3390_jpm13050718 crossref_primary_10_1038_s41467_023_43213_2 crossref_primary_10_1007_s13760_024_02486_0 crossref_primary_10_1016_j_jneuroim_2024_578290 crossref_primary_10_3390_ijms231911734 crossref_primary_10_4103_REGENMED_REGENMED_D_24_00005 crossref_primary_10_1002_advs_202305554 crossref_primary_10_3233_JPD_223241 crossref_primary_10_3233_JPD_223240 crossref_primary_10_3389_fncel_2025_1557645 crossref_primary_10_3390_ijms24065925 crossref_primary_10_1038_s41531_023_00626_6 crossref_primary_10_3233_JPD_240062 crossref_primary_10_3390_ijms241210040 crossref_primary_10_1002_alz_14291 crossref_primary_10_1155_2021_9923331 crossref_primary_10_1186_s12974_023_02748_3 crossref_primary_10_1007_s11055_023_01549_8 crossref_primary_10_1016_j_ecoenv_2022_114152 crossref_primary_10_1038_s41392_023_01353_3 crossref_primary_10_1016_j_nbd_2022_105700 crossref_primary_10_1186_s12974_024_03059_x crossref_primary_10_1016_j_cytogfr_2024_07_001 crossref_primary_10_1002_glia_24295 crossref_primary_10_1038_s41531_024_00643_z crossref_primary_10_1186_s12974_021_02296_8 crossref_primary_10_2174_0115672050389561250429112631 crossref_primary_10_1007_s00018_024_05402_0 crossref_primary_10_3389_fnins_2023_1083928 crossref_primary_10_1016_j_freeradbiomed_2024_07_018 crossref_primary_10_1016_j_pneurobio_2025_102797 crossref_primary_10_1007_s11427_021_2223_4 crossref_primary_10_3390_ijms23179739 crossref_primary_10_1186_s12883_025_04388_x crossref_primary_10_1126_scitranslmed_adm8563 crossref_primary_10_3233_JPD_240195 crossref_primary_10_3233_JPD_240353 crossref_primary_10_3390_cells13090749 crossref_primary_10_1007_s11011_025_01532_x crossref_primary_10_3390_ijms23158496 crossref_primary_10_1002_brb3_3373 crossref_primary_10_1016_j_nbd_2022_105798 crossref_primary_10_1016_j_phrs_2024_107168 crossref_primary_10_1038_s41421_024_00666_z crossref_primary_10_3390_ijms25073782 crossref_primary_10_1016_j_intimp_2025_114104 crossref_primary_10_1016_j_expneurol_2025_115142 crossref_primary_10_1186_s12915_025_02358_w crossref_primary_10_1002_acn3_51420 crossref_primary_10_3390_ijms24065792 crossref_primary_10_1111_cns_14682 crossref_primary_10_1186_s12974_025_03336_3 crossref_primary_10_1016_j_exger_2024_112415 crossref_primary_10_1007_s00281_022_00951_7 crossref_primary_10_1186_s12974_023_02723_y crossref_primary_10_31083_j_fbl2701020 crossref_primary_10_1038_s12276_023_00935_z crossref_primary_10_3390_nu14194108 crossref_primary_10_3390_cells14090644 crossref_primary_10_1111_bpa_13131 crossref_primary_10_1111_febs_17023 crossref_primary_10_1007_s12035_025_05153_4 crossref_primary_10_1016_j_cyto_2025_156954 crossref_primary_10_1093_brain_awae177 crossref_primary_10_1038_s41582_024_01043_w crossref_primary_10_1016_j_jneuroim_2023_578047 crossref_primary_10_1016_j_tins_2023_07_005 crossref_primary_10_1016_j_neuro_2023_03_002 crossref_primary_10_1097_MD_0000000000031813 crossref_primary_10_1016_j_ijrobp_2022_12_018 crossref_primary_10_1038_s41531_024_00790_3 crossref_primary_10_1126_scitranslmed_adk3225 crossref_primary_10_1186_s40478_023_01710_x crossref_primary_10_3389_fphar_2023_1265571 crossref_primary_10_3389_fgene_2022_914645 crossref_primary_10_1007_s00415_022_11190_z crossref_primary_10_3390_cells13181554 crossref_primary_10_1186_s12964_024_01509_w crossref_primary_10_3389_fimmu_2022_804674 crossref_primary_10_1002_mds_29798 crossref_primary_10_1038_s41392_024_01743_1 crossref_primary_10_3390_cells14171310 crossref_primary_10_1111_jpi_12916 crossref_primary_10_1007_s12035_023_03566_7 crossref_primary_10_3390_brainsci13020205 crossref_primary_10_1186_s40168_023_01685_w crossref_primary_10_1002_advs_202403892 crossref_primary_10_2147_JPR_S532016 crossref_primary_10_1126_sciimmunol_adu2910 crossref_primary_10_1186_s12974_024_03040_8 crossref_primary_10_1007_s12031_023_02182_3 crossref_primary_10_1038_s41531_024_00698_y crossref_primary_10_1038_s41467_023_39060_w crossref_primary_10_1111_cns_14063 crossref_primary_10_3389_fncel_2022_903469 crossref_primary_10_1016_j_ijbiomac_2025_139858 crossref_primary_10_1016_j_conb_2022_102646 crossref_primary_10_3389_fimmu_2022_878771 crossref_primary_10_1186_s13024_024_00770_4 crossref_primary_10_1186_s12974_025_03502_7 crossref_primary_10_3389_fimmu_2023_1281705 crossref_primary_10_1038_s41531_024_00735_w crossref_primary_10_3390_ijms242316766 crossref_primary_10_1002_jnr_25171 crossref_primary_10_1155_2022_1315248 crossref_primary_10_1016_j_jns_2022_120510 crossref_primary_10_1155_2022_7965433 crossref_primary_10_1016_j_bbi_2022_01_007 crossref_primary_10_1016_j_neuron_2023_07_015 crossref_primary_10_1038_s42003_023_05113_5 crossref_primary_10_1007_s11481_022_10056_5 crossref_primary_10_1097_CCO_0000000000000877 crossref_primary_10_1016_j_brainresbull_2023_110668 crossref_primary_10_1007_s12035_025_04750_7 crossref_primary_10_1016_j_cej_2024_152890 crossref_primary_10_3233_JPD_223153 crossref_primary_10_1007_s10571_025_01598_2 crossref_primary_10_3233_JPD_223152 crossref_primary_10_1186_s40001_024_02201_y crossref_primary_10_3390_ijms26115177 crossref_primary_10_1038_s41419_025_07336_2 crossref_primary_10_3389_fimmu_2022_872167 crossref_primary_10_3390_brainsci13071015 |
| ContentType | Journal Article |
| Copyright | The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. |
| Copyright_xml | – notice: The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. |
| DBID | 7X8 |
| DOI | 10.1093/brain/awab103 |
| DatabaseName | MEDLINE - Academic |
| DatabaseTitle | MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1460-2156 |
| GroupedDBID | --- -E4 -~X .2P .I3 .XZ .ZR 0R~ 1TH 23N 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 6PF 70D 7X8 AABZA AACZT AAIMJ AAJKP AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAVAP AAVLN AAWTL ABDFA ABEJV ABEUO ABGNP ABIVO ABIXL ABJNI ABKDP ABLJU ABMNT ABNHQ ABNKS ABPQP ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABXZS ABZBJ ACGFS ACIWK ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGKP ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AELWJ AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFGWE AFIYH AFOFC AFXAL AFYAG AGINJ AGKEF AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIJHB AJBYB AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ARIXL ATGXG AXUDD AYOIW BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BR6 BSWAC BTRTY BVRKM C45 CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EMOBN ENERS F5P F9B FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MHKGH ML0 N9A NGC NLBLG NOMLY NOYVH O9- OAUYM OAWHX OBOKY OCZFY ODMLO OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX RUSNO RW1 RXO TCURE TEORI TJX TLC TR2 VVN W8F WH7 WOQ X7H YAYTL YKOAZ YSK YXANX ZKX ~91 |
| ID | FETCH-LOGICAL-c364t-b2afb2180f1a1c2b9e6471a9f74a0b07908b71fee1014c6fb36e547b6608bfad2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 200 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000710991200021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1460-2156 |
| IngestDate | Thu Oct 02 11:51:57 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c364t-b2afb2180f1a1c2b9e6471a9f74a0b07908b71fee1014c6fb36e547b6608bfad2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8370411 |
| PQID | 2500374626 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2500374626 |
| PublicationCentury | 2000 |
| PublicationDate | 20210817 |
| PublicationDateYYYYMMDD | 2021-08-17 |
| PublicationDate_xml | – month: 08 year: 2021 text: 20210817 day: 17 |
| PublicationDecade | 2020 |
| PublicationTitle | Brain (London, England : 1878) |
| PublicationYear | 2021 |
| SSID | ssj0014326 |
| Score | 2.691365 |
| Snippet | α-Synuclein, a key pathological component of Parkinson's disease, has been implicated in the activation of the innate and adaptive immune system. This immune... |
| SourceID | proquest |
| SourceType | Aggregation Database |
| StartPage | 2047 |
| Title | CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease |
| URI | https://www.proquest.com/docview/2500374626 |
| Volume | 144 |
| WOSCitedRecordID | wos000710991200021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4Ft9EEDyFbpLdZPckUi1eLB4q9FYmL_GyVbfo33eSpog3wWs2gdlkdmZ2Jt98hFzxUDnhG8uAN4aVXnpWx45DrnJeg6yhFDaRTejRqJ5MmqeccOvytcqlTUyG2s1szJH30VXHVikYf9-8vbPIGhWrq5lCY5X0JIYyUav15KeKUEqR0UUFQ9emco9N_Invm0jA0IcvMDzxZf22w8m5DLf_K9YO2cphJb1d6MEuWfHtHtl4zIXzfeIGdyUd05im72hCi8w9TdJRVDHUigWCkULraGpx6fxLakidRnEW0Jgj8DQx59BZoBEunZBj1x3NVZ4D8jy8Hw8eWCZYYFaqcs6MgGDQxxeBA7fCNF6hr4Im6BIKU-imqI3mwftI6GtVMFL5qtRGKXwQwIlDstbOWn9EKAhVVyLguIvQ3tpwZ5XAo8fFVgI_JpfL_ZuiAsfXhdaj4NOfHTz5w5xTsinirZLYlFafkV7Aj9Sfk3X7OX_tPi7S-X8DMKe8UQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CD4+T+cells+mediate+brain+inflammation+and+neurodegeneration+in+a+mouse+model+of+Parkinson%27s+disease&rft.jtitle=Brain+%28London%2C+England+%3A+1878%29&rft.au=Williams%2C+Gregory+P&rft.au=Schonhoff%2C+Aubrey+M&rft.au=Jurkuvenaite%2C+Asta&rft.au=Gallups%2C+Nicole+J&rft.date=2021-08-17&rft.issn=1460-2156&rft.eissn=1460-2156&rft.volume=144&rft.issue=7&rft.spage=2047&rft_id=info:doi/10.1093%2Fbrain%2Fawab103&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2156&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2156&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2156&client=summon |